West Pharma’s New Org Chart: Visualizing the Lagarde Transition

 A CEO transition at a $3 billion injectable-drug components manufacturer is a structural reset that arrives faster than most enterprise sellers can rebuild their account intelligence. 

West Pharmaceutical Services, which delivers over 41 billion components and devices annually, just replaced the executive who shaped its strategy for nearly a decade. The successor was hired specifically to accelerate high-margin contract manufacturing and GLP-1 delivery systems. 

For enterprise sales teams, this is not merely an executive change. It signals the beginning of a new operating phase. 

As demand for injectable therapies accelerates, particularly around GLP-1 treatments and advanced biologics, the internal priorities, budget flows, decision pathways, and stakeholder influence networks inside West are likely to evolve. Sellers relying on historical relationships or static account maps may soon discover that yesterday's buying committee no longer controls tomorrow's decisions. 

That’s why understanding this transition requires visibility into the pharmaceutical organizational hierarchy that is actively being reshaped. 

Why Does a Single Executive Change Make an Entire Account Strategy Irrelevant? 

Eric M. Green is retiring from his roles as President, CEO, and Board Chair.

Michel Lagarde, formerly Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, takes over all three starting August 31, 2026. 

Robert F. Friel, currently Lead Independent Director, becomes Board Chair the same day. 

That is three governance seats changing hands simultaneously, a cascade most CRM systems never capture: 

• Budget reauthorization resets as new CEOs typically reassess capital allocation within two quarters, so deals "in motion" may need re-justifying.

• Reporting lines reshuffle once Lagarde installs his own lieutenants.

• Procurement risk tolerance shifts, since a leader from contract manufacturing and pharma services brings different vendor instincts than an internal promotion would.

Lagarde himself framed this moment as pivotal, with AI reshaping therapy development and accelerating demand for reliable, high-quality injectable delivery. That's a CEO signaling that operational throughput, not legacy relationships, will drive every major decision going forward. 

For sellers, the account plan written six months ago is now testing a hypothesis that no longer holds. 

What Breaks First When a Pharma Org Chart Is Mapped Manually Mid-Transition? 

Manual account mapping was built for accuracy at a single point in time, which is exactly what a leadership transition destroys. 

Most teams maintain account intelligence through LinkedIn searches and intuition, fine when an organization is stable, but it fails the moment a pharma company org chart starts moving. By the time research reflects a new VP of Operations, that VP has already made vendor decisions without the seller in the room. 

A pharma company organizational structure during a CEO transition is a live system with shifting authority that rarely announces itself through press releases. It shows up quietly: 

• Internal title changes that generate new approval authority without news coverage

• Departures of executives aligned with the outgoing CEO's priorities

• Promotions matching the incoming CEO's stated focus, here, contract manufacturing and high-volume injectable delivery

So what is a pharma company org chart, really, in this context? 

It is not a static diagram, but a moving probability model of who holds budget authority by the time your deal needs signature. A title from last quarter doesn't tell you who approves next quarter's contract manufacturing commitment, and that's the only question that drives revenue. 

Why Do AI-Generated Org Maps Outperform Static Charts as Buyer Behavior Shifts? 

GLP-1 demand has compressed pharma manufacturing buying cycles industry-wide. Evaluations that once took 12 to 18 months are shrinking because delivery-device capacity has become a bottleneck and West's pivot toward high-margin contract manufacturing is a direct response. 

Faster cycles plus a leadership transition create a narrow window where the wrong contact gets prioritized and the deal stalls. This is where GenAI-driven org intelligence changes seller leverage, not by replacing relationship-building, but by removing guesswork about who to build it with: 

• Surfaces authority shifts near real time, cross-referencing filings, announcements, and promotions instead of waiting for a profile update

• Flags influence without formal title changes, identifying executives whose function now aligns with the incoming CEO's priorities

• Models second- and third-level reporting changes, where most enterprise deals are actually evaluated before reaching executive sign-off

The CEO is rarely the buyer. Lagarde sets direction; the people translating that into procurement criteria sit two levels below him. Mapping only the C-suite during a transition means optimizing for the wrong layer. 

How Should Sellers Navigate This Account From Targeting to Post-Sale? 

Treat the transition as a sequence, instead of an event. 

Step 1: Navigation: 

Rebuild the account map around function. Identify who in operations and supply chain has gained visible authority tied to contract manufacturing and GLP-1 priorities, and cross-reference against board signals like Friel's elevation. 

Step 2: Approach: 

Outreach referencing the transition directly, framed around operational continuity rather than congratulations, lands differently than templated messaging. 

Step 3: Deal-closing: 

Expect procurement criteria to shift mid-cycle. Build flexibility into proposals around capacity scalability, since that maps directly to the incoming CEO's mandate. 

Step 4: Post-sale: 

Most sellers disengage here, and that's the real risk. Org structures that shifted once during a transition often shift again within 12 to 18 months. Maintaining a live org map post-sale protects against losing champions to reorganization and missing expansion when new budget authority emerges.

What is a Pharma Company Org Chart Becoming in The Age of Organizational Intelligence?  

Historically, pharma company org charts functioned as reference documents. Today, they are becoming strategic sales infrastructure. 

The shift underway at West Pharmaceutical Services illustrates why. 

A leadership transition at the top creates cascading changes throughout manufacturing, operations, procurement, quality, innovation, and strategic planning functions. Enterprise sellers who recognize these changes early gain a visibility advantage that traditional prospecting methods cannot provide. 

The competitive edge is no longer access to contacts, rather it is understanding how organizational influence moves before the market fully recognizes where it has gone. 

Let’s Address a Few Frequently Asked Questions (FAQs)

Q. What is a pharma company org chart, really, in an enterprise sales context?

It's a functional map of decision authority, not a directory of titles. The useful version shows who influences procurement criteria and budget sign-off, which often differs from the formal reporting structure. 

Q. How often should org chart intelligence be refreshed during an active leadership transition?

During the first two to three quarters after a transition like this one, monthly refreshes are reasonable. Authority shifts faster than annual org chart updates can capture, especially in the layer below the C-suite. 

Q. Does a new CEO from outside the company change vendor evaluation criteria immediately?

Not immediately, but within the first six months, as the new leader's priorities filter into procurement language. Lagarde's stated focus on AI-accelerated therapy development and reliable delivery capacity is a strong early signal of what future RFPs will emphasize. 

Q. Should sellers prioritize the new CEO directly during the transition window?

Generally no. Operational and manufacturing strategy leaders two levels below the CEO typically own the evaluation process. Executive-level outreach can support a deal but rarely originates it. 

The accounts that convert fastest will always be the ones whose intelligence moved at the same speed as the org chart itself. If your account mapping still treats pharma organizational hierarchy as a static document, CLICK HERE to see how BizKonnect's GenAI-driven org intelligence keeps enterprise sellers ahead of exactly this kind of shift.